Nexalin Technology, Inc. experienced a surge in shares on Friday afternoon following the announcement of a new patent awarded by the United States Patent and Trademark Office (USPTO). The patent covers their advanced Deep Intracranial Frequency Stimulation (DIFS) medical device, which is a non-invasive technology aimed at treating Alzheimer’s and dementia.
The USPTO granted U.S. Patent No. 12,011,591 to Nexalin Technology, highlighting their intellectual property expansion and addressing the growing market for dementia treatment globally. Mark White, CEO of Nexalin Technology, emphasized the importance of this patent in expanding their reach and transforming standard care for mental health disorders like Alzheimer’s and dementia.
Nexalin’s technology has shown clinical benefits for a range of neurological conditions, including treatment-resistant depression, migraines, anxiety, insomnia, addiction, and PTSD. The new patent underscores the potential of DIFS technology to revolutionize dementia treatment on a global scale.
At the time of writing, Nexalin Technology shares were trading at $2.15, up by 97.3% according to Benzinga Pro. This news showcases the exciting advancements in medical technology and the potential for innovative treatments in the field of mental health disorders.
In summary, Nexalin Technology’s new patent adds value to its existing portfolio and opens up new opportunities for growth in the global market for dementia treatment. With its advanced DIFS technology and proven clinical benefits across various neurological conditions
